Publicación:
Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia

Vista sencilla de ítem
dc.contributor.authorFaccini Martínez, Álvaro Adolfo
dc.contributor.authorRivero, Ricardo
dc.contributor.authorGaray Montalvo, Evelin
dc.contributor.authorGarcía Pérez, Alejandra
dc.contributor.authorMattar Velilla, Ameth Salim
dc.contributor.authorBotero, Yesica
dc.contributor.authorGaleano Anaya, Ketty Esther
dc.contributor.authorMiranda Regino, Jorge Luis
dc.contributor.authorMartínez Bravo, Caty Milena
dc.contributor.authorGuzmán Terán, Camilo Antonio
dc.contributor.authorContreras, Héctor
dc.contributor.authorKerguelen, Hugo
dc.contributor.authorMoscote, María
dc.contributor.authorBrango Tarra, Eimi Johana
dc.contributor.authorContreras Cogollo, Veronica
dc.contributor.corporatenameCorporación Universitaria del caribe - CECAR
dc.contributor.researchgroupSalud Pública y Auditoría en Salud
dc.date.accessioned2025-09-01T22:16:18Z
dc.date.issued2020
dc.description.abstractObjectives: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region. Methods: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae. Results: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity. Conclusions: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus.
dc.description.researchareaAuditoría en Salud
dc.description.researchareaSalud Pública
dc.format.extent3 páginas
dc.format.mimetypeapplication/pdf
dc.identifier.eissn1201-9712
dc.identifier.urihttps://repositorio.cecar.edu.co/handle/cecar/10831
dc.language.isoeng
dc.publisher.placeColombia
dc.relation.citationendpage193
dc.relation.citationstartpage191
dc.relation.citationvolumeVolumen 101
dc.relation.ispartofjournalInternational Journal of Infectious Diseases
dc.relation.referenceshttps://coronavirus.jhu.edu/map.html. [cited 2020 Sept 21].
dc.relation.referencesArrieta G, Mattar S, Villero-Wolf Y, et al. Evaluation of serological test of Zika in an endemic area of flavivirus in the Colombian Caribbean. Ann Clin Microbiol Antimicrob 2019;18(1):29.
dc.relation.referencesChams N, Chams S, Badran R, et al. COVID-19: a multidisciplinary review. Front Public Health 2020;8:383.
dc.relation.referencesHanson KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19:serologic testing. Clin Infect Dis 2020; ciaa1343.
dc.relation.referencesLustig Y, Keler S, Kolodny R, et al. Potential antigenic cross-reactivity between SARSCoV-2 and Dengue viruses. Clin Infect Dis 2020; ciaa1207.
dc.relation.referencesMora-Salamanca AF, Porras-Ramírez A, De la Hoz Restrepo FP. Estimating the burden of arboviral diseases in Colombia between 2013 and 2016. Int J Infect Dis 2020;97:81–9.
dc.relation.referencesNunthavichitra S, Prapaso S, Luvira V, et al. Case report: COVID-19 presenting as acute undifferentiated febrile illness-a tropical world threat. Am J Trop Med Hyg 2020;103(1):83–5.
dc.relation.referencesRodriguez-Morales AJ. Zika: the new arbovirus threat for Latin America. J Infect Dev Ctries 2015;9(6):684–5.
dc.relation.referencesRodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and metaanalysis. Travel Med Infect Dis 2020;34:101623.
dc.relation.referencesSpinicci M, Bartoloni A, Mantella A, et al. Low risk of serological cross-reactivity between dengue and COVID-19. Mem Inst Oswaldo Cruz 2020;115:e200225.
dc.rightsDerechos reservados - Corporación Universitaria de Caribe - CECAR
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2
dc.rights.licenseAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourcehttps://doi.org/10.1016/j.ijid.2020.09.1451 1
dc.subject.proposalDiagnosis
dc.subject.proposalEndemic diseases
dc.subject.proposalArbovirus infection
dc.subject.proposalValidation study
dc.titleSerological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombiaeng
dc.typeArtículo de revista
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/article
dc.type.redcolhttp://purl.org/redcol/resource_type/ART
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia.pdf
Tamaño:
268.52 KB
Formato:
Adobe Portable Document Format
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
14.49 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

BAF. Salud Pública y Auditoria en Salud (SPAS)